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Edited by Gianni CesareniAbstract The Type I insulin-like growth factor receptor is a
physiological receptor for insulin-like growth factor II (IGF-II).
To characterize the molecular basis of the receptor’s ligand
binding properties, we have examined the eﬀects of alanine
mutations of residues in the ligand binding site of the receptor on
its aﬃnity for IGF-II. The functional epitope for IGF-II
comprises residues in the N-terminal L1 domain and residues
at the C-terminus of the a subunit. Cysteine rich domain residues
do not appear to be critical for IGF-II binding.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Insulin-like growth factors I and II (IGF-I and II) are
homologous peptide growth factors that are major regulators
of growth in vertebrates [1]. Transgenic experiments indicate
that both peptides exert their physiological eﬀects through
binding to the Type I insulin-like growth factor receptor [1].
This receptor binds both peptides with high aﬃnity although
its aﬃnity for IGF-I has been reported to be 2–5 times higher
than its aﬃnity for IGF-II [2–5].
The Type I IGF receptor is a member of the insulin receptor
sub-class of receptor tyrosine kinases [6]. Recently, the struc-
ture of an N-terminal fragment of the receptor, comprising the
L1, cysteine rich and L2 domains (amino acids 1–460), has
been reported [7]. While this fragment is devoid of ligand
binding activity, a mini-receptor formed by the fusion of this
fragment to a peptide (amino acids 692–702) from the C-ter-
minus of the receptor a subunit binds IGF-I with an aﬃnity
near to that of the recombinant secreted extra-cellular domain
[8]. This indicates that these fragments form the minimal ele-
ments of a major IGF-I binding site of the receptor. We have
recently deﬁned the functional epitope of this IGF-I binding
site using alanine scanning mutagenesis [9]. In the present
study, in order to gain further insight into the molecular basis* Corresponding author. Present address: Departments of Nutrition
and Biochemistry, Case Western Reserve University, 10900 Euclid
Avenue, Cleveland, OH 44106-4906, USA. Fax: +1-216-368-6644.
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Abbreviations: IGF-I, insulin-like growth factor I; IGF-II, insulin-like
growth factor II; 125I-[Tyr31] IGF-I, insulin-like growth factor I radio-
iodinated on Tyrosine 31
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we have used alanine scanning mutagenesis to determine its
functional epitope for IGF-II.2. Materials and methods
2.1. Materials
All oligonucleotides were purchased from DNA technology
(Aarhus, Denmark). Restriction and modifying enzymes were from
New England Biolabs (Beverly, MA). Recombinant IGF-I and IGF-II
(receptor grade) were from Gro Pep (Adelaide, Australia). High per-
formance liquid chromatography puriﬁed mono-iodinated insulin-like
growth factor I radio-iodinated on Tyrosine 31 (125I-[Tyr31] IGF-I)
was from Novo Nordisk A/S [10]. Protease inhibitors were from Roche
Molecular Biochemicals (Mannheim, Germany). Medium and serum
for tissue culture were from Life Technologies A/S (Tastrup, Den-
mark). Peak Rapid cells (293 cells constitutively expressing SV40 large
T antigen) were purchased from Edge Biosystems (Gaithersburg, MD).
The mammalian expression vector pcDNA3-zeo(+) was from Invit-
rogen (San Diego, CA). The hybridoma secreting monoclonal anti-
body 24–31 directed toward the IGF-I receptor a-subunit was a
generous gift of Dr. M.Soos and Dr. K. Siddle (University of Cam-
bridge, UK). Protein A-puriﬁed IgG from the hybridoma medium was
kindly provided by Dr. P. Jørgensen (Novo Nordisk A/S, Bagsvrd,
Denmark). The construction and transient expression of alanine
mutants of Type I insulin-like growth factor receptor cDNAs in 293
Peak Rapid cells has been described in detail [1].
2.2. IGF-II binding assays
IGF-II binding assays were performed by a modiﬁcation of methods
previously used for equilibrium binding assays of the insulin and IGF-I
receptors [9,11]. Secreted recombinant IGF-I receptor was immobilized
from the conditioned media of transiently transfected Peak Rapid cells
in antibody coated 96 well microtiter plates as previously described
[9,11]. 125I-[Tyr31] IGF-I (12 pmol/L) and unlabeled IGF-II (0–100
nmol/L) were incubated with immobilized receptor for 16 h at 25 C in
a total volume of 100 lL. Bound radioactivity was determined after the
plates had been washed three times with ice cold wash buﬀer.
Dissociation constants for IGF-II were determined by curve-ﬁtting
using a single site heterologous competition model as described by
Wang [12], written in Excel. Dissociation constants for IGF-I used for
the ﬁtting of data for wild type and mutant receptors were taken from
our previously published study [9].3. Results and discussion
Wild type secreted IGF-I receptor cDNAs were expressed by
transient transfection in 293 Peak Rapid cells. Initial attempts
to evaluate IGF-II binding were made with either commercial
mono-iodinated IGF-II (Amersham) or HPLC puriﬁed mono-
iodinated IGF-II produced at Novo Nordisk A/S. Neither
were of suﬃcient quality for use in homologous competitive
binding assays with unlabeled IGF-II (data not shown). Thus,blished by Elsevier B.V. All rights reserved.
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125I-[Tyr31] IGF-I by unlabeled IGF-II. The Kd of wild type
IGF-II determined in this assay was 2.9 0.2 nM (mean-
s S.E.M., n ¼ 8); Kd for IGF-I determined in parallel ex-
periments was 0.7 0.06 nM (means S.E.M., n ¼ 8). This 4-
to 5-fold diﬀerence in aﬃnity is similar to that previously re-
ported for the full length receptor [2–5]. In the experiments
described below, alanine mutations resulting in a Kd for IGF-II
of greater than 5.8 nM were considered to signiﬁcantly disrupt
ligand receptor interactions [13].
cDNAs encoding alanine mutations of all ligand accessible
residues located in candidate IGF-I binding regions of the
Type I IGF receptor (L1, cysteine rich and L2 domains) and
amino acids of 692–702 have been previously described [9]. In
the N-terminal fragment (L1, cysteine rich and L2 domains),
these are all solvent accessible residues located in the putative
binding pocket of the receptor [7] and are limited to the L1
domain and the cysteine rich domain (CRD) (amino acids
1–284) on the basis of the reported size of the IGF-I molecule
[14–16] and previous mutational analyses of IGF-I–Type I
IGF receptor interactions [9,17]; in the crystal. structure of the
N-terminal fragment of the receptor [7], IGF-I is not large
enough to simultaneously contact the part of the IGF-I func-
tional epitope [9] most distant from the L2 domain (amino
acids Asn11, Leu33, Arg59 and Phe90) and residues of the L2
domain even with bridging by water molecules.
Alanine mutant cDNAs were expressed by transient trans-
fection; cDNAs encoding alanine mutations of Tyr54 and Thr93Table 1
Eﬀects of alanine mutations on the aﬃnity of the Type I insulin-like growth
L1 domain Cysteine rich domain
Mutanta Kd (nM)b Kd Mut/Kd WTc Mutanta Kd (nM)b
D8 7.5 0.4 2.6 0.2 R240 1.4 0.1
R10 2.9 0.1 1.0 0.02 F241 0.5 0.04
N11 9.5 1.1 3.3 0.4 E242 1.2 0.1
D12 1.2 0.1 0.4 0.02 F251 0.8 0.2
Y28 10.3 1.1 3.6 0.4 I255 1.6 0.2
H30 12.2 1.8 4.2 0.6 L256 3.4 0.2
L32 7.3 0.5 2.5 0.2 S257 2.6 0.4
L33 29.3 3.9 10.1 1.3 E259 3.1 0.2
S35 2.5 0.2 0.9 0.1 S260 2.0 0.4
Y54 ND ND S261 3.8 0.2
L56 15.5 1.5 5.3 0.5 D262 1.9 0.3
F58 10.9 0.7 3.7 0.2 S263 3.3 0.3
R59 23.6 2.0 8.1 0.7 E264 3.1 0.3
K60 3.5 0.8 1.2 0.3 F266 2.6 0.2
W79 2.2 0.3 0.8 0.1 H269 2.1 0.1
L81 2.9 0.1 1.0 0.05 D270 2.3 0.4
F82 3.5 0.3 1.2 0.1 E272 3.1 0.3
Y83 2.0 0.2 0.7 0.1 M274 1.7 0.3
N84 0.8 0.2 0.3 0.06 Q275 4.2 0.4
Y85 1.0 0.1 0.3 0.04 E276 3.3 0.6
V88 2.6 0.1 0.9 0.02 S279 2.2 0.5
F90 8.7 1.4 3.0 0.5 F281 3.2 1
E91 2.6 0.3 0.9 0.1 I282 3.3 0.4
T93 ND ND R283 1.6 0.4
R112 2.5 0.1 0.9 0.05 N284 3.1 0.
E114 4.5 0.2 1.6 0.06
K115 1.8 0.3 0.6 0.1
Y138 2.9 0.1 1.0 0.03
V140 4.5 0.2 1.5 0.1
ND: mutants not secreted.
*Aﬃnity too low to be accurately determined, see text.
aAmino acids mutated are designated by the single letter code.
bResults are expressed as meansS.E.M. of 3–4 independent determination
cResults are expressed as the ratio of the Kd of the mutant to the Kd of thewere not transfected as we have previously demonstrated that
these mutations are not expressed due to perturbation of pro-
tein folding [9]. Expression of all mutants was conﬁrmed by the
binding of 125I-IGF-II with the exception of the alanine mutant
of Phe701 which failed to exhibit signiﬁcant speciﬁc tracer
binding, even after 20-fold concentration of conditioned me-
dium from transfected cells (data not shown). Expression of this
mutant was conﬁrmed by Western blotting (data not shown).
The results of the Kds of the mutant receptors are shown in
Table 1. In L1 alanine mutations of Asp8, Asn11, Tyr28, His30,
Leu32, Leu33, Leu56, Phe58, Arg59 and Phe90 produce signiﬁ-
cant decrease in aﬃnity for IGF-II. Only mutations of Leu33,
Leu56 and Arg59 produced increases in Kd of 5-fold or greater.
As shown in Fig. 2A, all residues, whose mutation compro-
mises aﬃnity for IGF-II, form a continuous footprint on the
base of the L1 domain of the receptor, consistent with par-
ticipating in a ligand binding site for a small protein.
In the cysteine rich domain, none of the alanine mutations
expressed caused any signiﬁcant compromise in aﬃnity for
IGF-II (Table 1).
At the C-terminus of the a subunit, alanine mutations of
Phe692, Glu693, Asn694, Phe695, His697, Asn698, and Ile700 pro-
duced 4- to 27-fold increases in Kd (Table 1). As discussed
above the alanine mutant of Phe701 failed to bind IGF-II de-
spite normal expression of this mutant protein, indicating that
its aﬃnity for IGF-II is too low to be measured by the meth-
odology employed in this study. This would suggest that its Kd
for IGF-II is at least a 100-fold greater than that of the wildfactor receptor for IGF-II
a subunit C-terminus
Kd Mut/Kd WTc Mutanta Kd (nM)b Kd Mut/Kd WTc
1.4 0.1 F692 77.7 7.0 26.7 2.4
0.5 0.04 E693 39.0 10.1 13.4 3.5
1.2 0.1 N694 78.8 7.8 27.1 2.7
0.8 0.2 F695 42.9 8.3 14.7 2.9
0.5 0.06 L696 33.2 5.9 11.4 2.0
1.2 0.1 H697 28.0 2.0 9.6 0.7
0.9 0.2 N698 12.5 1.7 4.3 0.6
1.0 0.1 S699 2.0 0.1 0.7 0.04
0.7 0.1 I700 17.0 1.5 5.8 0.5
1.3 0.1 F701  
















wild type receptor (Kd Mut/Kd WT).
Fig. 1. Comparison of the functional epitopes for IGF-II and IGF-I.
The eﬀects of alanine mutations of amino acids, which form the Type I
IGF-receptor ligand binding site, on aﬃnity for IGF-II and IGF-I are
compared. Results are presented as ratios of the dissociation constant
of the mutant receptor to that of the wild type receptor. Data for IGF-
I binding are taken from [9]. Results for both ligands represent
meansS.E.M. of 3–4 independent determinations. The amino acids
mutated to alanine are designated by the single letter code. L1 desig-
nates amino acids located in the cysteine rich domain and CRD amino
acids in the cysteine rich domain. For the alanine mutant of Phe701, the
Kd ratios for both IGF-II and IGF-I have been arbitrarily assigned
values of 100 (see text for detailed discussion).
Fig. 2. Comparison of the structures of the functional epitopes of the
L1 and cysteine rich domains for IGF-II and IGF-I binding. The Ca
backbone of the L1 and CRDs is shown as a ribbon representation.
The amino acids forming the functional epitopes for IGF-II (A) and
IGF-I (B) are shown in space-ﬁlling representation. Alanine mutations
of amino acids colored green produced a 2- to 5-fold reduction in af-
ﬁnity, those colored yellow produced a 5- to 10-fold reduction and
those colored red produced a greater than 10-fold reduction. Amino
acids are designated by the single letter code. This ﬁgure was prepared
with the Swiss PDB Viewer [18].
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free energy of the ligand receptor interaction is provided by
this sub-domain of the receptor ligand binding site.
We have previously characterized the functional epitope of
the Type I insulin-like growth factor receptor IGF-I binding
site by alanine scanning mutagenesis [9]. It is of interest to
compare the functional epitopes for both ligands. The results
of this comparison for the L1, cysteine rich and C-terminal a
subunit domains are shown in Fig. 1. Both functional epitopes
are qualitatively very similar but certain residues appear to
participate selectively in the binding of one or other ligand.
The most striking diﬀerence between them is that the cysteine
rich domain residues Arg240, Phe241, Glu242 and Phe251, which
together with Trp79 from the L1 domain form a hydrophobic
patch at the base of the IGF-I functional epitope (Fig. 2B and
[9]), make no signiﬁcant energetic contribution to the binding
of IGF-II. In the L1 domain Trp79, which compromises aﬃnity
for IGF-I, is not involved in IGF-II binding (Fig. 1). In con-
trast, alanine mutation of Leu32, which contributes to IGF-II
binding, has no impact on IGF-I receptor interaction (Fig. 1).
When the L1 residues contributing to the functional epitopes
are compared in the context of the topology of this region of
the receptor (Fig. 1), interesting diﬀerences emerge for the two
ligands. Alanine mutations of residues in the ﬁrst (Asp8 and
Asn11) and fourth turns (Phe90) of the L1 domain b helix are
more disruptive of IGF-I binding than IGF-II binding (Figs. 1
and 2). In contrast, alanine mutations of residues in the second
(Tyr28, His30, Leu32 and Leu33) and third turns (Leu56, Phe58
and Arg59) are more deleterious to IGF-II binding (Figs. 1 and
2).
Diﬀerences in eﬀects of alanine substitutions of residues at
the C-terminus of the a subunit on binding of IGF-I and IGF-
II are also observed. Alanine mutation of Phe695 resulted in 15-
fold reduction in aﬃnity for IGF-II but was without eﬀect on
IGF-I binding (Fig. 1). Alanine mutations of Phe692, Glu693,
Asn694 and His697 have more pronounced eﬀects on aﬃnity for
IGF-II than for IGF-I (Fig. 1). The reverse is seen for muta-tions of Leu696, Asn698 and Ile700 (Fig. 1). The eﬀect of alanine
mutation of Phe701 was so disruptive that it was impossible to
quantitate Kds for either IGF-I or IGF-II.
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IGF-II binding site of the Type I IGF-I receptor which is
composed of elements of the L1 domain, and the C-terminus
of the a subunit of the receptor. This contrasts with the
functional epitope of receptor for IGF-I, which contains ele-
ments of the cysteine rich domain in addition to those involved
in IGF-II binding. The diﬀerences between the two functional
epitopes indicate that the two peptides utilize diﬀerent molec-
ular mechanisms to bind to the same ligand binding site of the
receptor. It is tempting to conclude that this diﬀerence in the
functional epitopes, particularly the absence of interaction of
IGF-II with the receptor cysteine rich domain, accounts for the
diﬀerence in aﬃnities of this receptor for the two ligands.
However, deﬁnitive conﬁrmation of this conclusion will re-
quire elucidation of the structures of the peptide–receptor
complexes and detailed analyses of the energetic contributions
of the residues forming the functional epitopes of both ligands
and also of the receptor.Acknowledgements: We are grateful to Drs. M. Soos and K. Siddle
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